Christopher DeSouza
Concepts (386)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Endothelium, Vascular | 44 | 2023 | 843 | 8.910 |
Why?
| Cell-Derived Microparticles | 13 | 2023 | 57 | 7.330 |
Why?
| Vasodilation | 28 | 2023 | 419 | 6.210 |
Why?
| Endothelin-1 | 16 | 2023 | 167 | 5.630 |
Why?
| Vasoconstriction | 13 | 2023 | 177 | 4.020 |
Why?
| Endothelial Cells | 15 | 2023 | 681 | 3.780 |
Why?
| Fibrinolysis | 15 | 2023 | 158 | 3.350 |
Why?
| Hypertension | 13 | 2023 | 1056 | 2.940 |
Why?
| Nitric Oxide | 13 | 2023 | 823 | 2.790 |
Why?
| Sleep Deprivation | 6 | 2021 | 166 | 2.760 |
Why?
| Forearm | 17 | 2021 | 112 | 2.700 |
Why?
| Tissue Plasminogen Activator | 16 | 2023 | 225 | 2.640 |
Why?
| Vasodilator Agents | 20 | 2023 | 302 | 2.610 |
Why?
| Obesity | 19 | 2023 | 2507 | 2.430 |
Why?
| Overweight | 9 | 2018 | 471 | 2.360 |
Why?
| Aging | 36 | 2011 | 1618 | 2.200 |
Why?
| MicroRNAs | 6 | 2023 | 600 | 2.180 |
Why?
| Spinal Cord Injuries | 4 | 2023 | 174 | 2.100 |
Why?
| Human Umbilical Vein Endothelial Cells | 6 | 2023 | 89 | 2.080 |
Why?
| Exercise | 31 | 2023 | 1644 | 2.040 |
Why?
| Middle Aged | 106 | 2024 | 26719 | 1.870 |
Why?
| Prehypertension | 5 | 2015 | 24 | 1.780 |
Why?
| Cardiovascular Diseases | 11 | 2021 | 1727 | 1.740 |
Why?
| Acetylcholine | 16 | 2023 | 166 | 1.650 |
Why?
| Sleep | 5 | 2021 | 631 | 1.620 |
Why?
| Regional Blood Flow | 23 | 2023 | 424 | 1.600 |
Why?
| HIV Envelope Protein gp120 | 3 | 2019 | 56 | 1.590 |
Why?
| Blood Pressure | 19 | 2021 | 1538 | 1.580 |
Why?
| Apoptosis | 14 | 2023 | 2362 | 1.500 |
Why?
| Polycythemia | 2 | 2021 | 23 | 1.490 |
Why?
| Stem Cells | 8 | 2012 | 545 | 1.470 |
Why?
| Male | 89 | 2024 | 55554 | 1.290 |
Why?
| Nitric Oxide Synthase Type III | 7 | 2023 | 184 | 1.270 |
Why?
| tat Gene Products, Human Immunodeficiency Virus | 2 | 2019 | 20 | 1.250 |
Why?
| Nitroprusside | 15 | 2021 | 64 | 1.230 |
Why?
| C-Reactive Protein | 7 | 2015 | 362 | 1.230 |
Why?
| Metabolic Syndrome | 4 | 2016 | 321 | 1.230 |
Why?
| Circulating MicroRNA | 2 | 2019 | 24 | 1.220 |
Why?
| Postmenopause | 17 | 2023 | 303 | 1.170 |
Why?
| Atherosclerosis | 2 | 2023 | 341 | 1.160 |
Why?
| Cell Movement | 8 | 2014 | 868 | 1.140 |
Why?
| Nebivolol | 2 | 2017 | 9 | 1.120 |
Why?
| Platelet Endothelial Cell Adhesion Molecule-1 | 3 | 2011 | 57 | 1.060 |
Why?
| Humans | 127 | 2024 | 114623 | 1.060 |
Why?
| Peptides, Cyclic | 7 | 2013 | 253 | 1.060 |
Why?
| Caspase 3 | 5 | 2017 | 235 | 1.050 |
Why?
| Adult | 64 | 2023 | 30528 | 1.020 |
Why?
| Female | 78 | 2023 | 59466 | 0.960 |
Why?
| Vasoconstrictor Agents | 6 | 2023 | 112 | 0.950 |
Why?
| Fibrin Fibrinogen Degradation Products | 2 | 2023 | 80 | 0.890 |
Why?
| Aged | 60 | 2021 | 19061 | 0.870 |
Why?
| Dietary Fats | 2 | 2015 | 287 | 0.830 |
Why?
| Inflammation Mediators | 4 | 2021 | 477 | 0.820 |
Why?
| Blood Coagulation | 2 | 2021 | 218 | 0.790 |
Why?
| Estrogen Replacement Therapy | 9 | 2003 | 116 | 0.750 |
Why?
| Altitude | 3 | 2021 | 432 | 0.740 |
Why?
| Vasomotor System | 1 | 2021 | 39 | 0.730 |
Why?
| Vascular Diseases | 1 | 2023 | 230 | 0.730 |
Why?
| Case-Control Studies | 11 | 2021 | 3003 | 0.700 |
Why?
| Oxidative Stress | 7 | 2021 | 1076 | 0.690 |
Why?
| Cross-Sectional Studies | 22 | 2023 | 4405 | 0.690 |
Why?
| Physical Endurance | 15 | 2024 | 232 | 0.680 |
Why?
| Hemodynamics | 8 | 2021 | 1012 | 0.670 |
Why?
| Acclimatization | 1 | 2021 | 149 | 0.670 |
Why?
| Ascorbic Acid | 3 | 2021 | 110 | 0.660 |
Why?
| Telomere | 3 | 2010 | 202 | 0.660 |
Why?
| Cells, Cultured | 8 | 2021 | 3881 | 0.650 |
Why?
| Physical Fitness | 11 | 2005 | 179 | 0.630 |
Why?
| T-Lymphocyte Subsets | 2 | 2011 | 383 | 0.630 |
Why?
| Blood Glucose | 7 | 2019 | 1819 | 0.620 |
Why?
| Endothelium | 3 | 2020 | 110 | 0.620 |
Why?
| Hematopoietic Stem Cells | 2 | 2011 | 343 | 0.600 |
Why?
| Dose-Response Relationship, Drug | 8 | 2017 | 1842 | 0.590 |
Why?
| Metoprolol | 1 | 2017 | 37 | 0.580 |
Why?
| HIV | 1 | 2019 | 208 | 0.580 |
Why?
| Hyperglycemia | 2 | 2018 | 291 | 0.580 |
Why?
| Plethysmography | 5 | 2017 | 103 | 0.570 |
Why?
| HIV Infections | 4 | 2019 | 2469 | 0.570 |
Why?
| Body Mass Index | 15 | 2017 | 1956 | 0.560 |
Why?
| Stress, Physiological | 2 | 2017 | 378 | 0.560 |
Why?
| Cytokines | 4 | 2020 | 1840 | 0.550 |
Why?
| Receptor, Endothelin A | 2 | 2014 | 59 | 0.550 |
Why?
| Cellular Senescence | 1 | 2018 | 152 | 0.550 |
Why?
| Biomarkers | 11 | 2023 | 3408 | 0.550 |
Why?
| Enzyme Inhibitors | 5 | 2017 | 750 | 0.520 |
Why?
| Nitric Oxide Synthase | 4 | 2017 | 209 | 0.510 |
Why?
| Bradykinin | 7 | 2015 | 42 | 0.500 |
Why?
| Blood Pressure Determination | 2 | 2016 | 122 | 0.500 |
Why?
| Gender Identity | 2 | 2006 | 102 | 0.490 |
Why?
| Plasminogen Activator Inhibitor 1 | 6 | 2023 | 83 | 0.490 |
Why?
| Diet, High-Fat | 2 | 2018 | 225 | 0.480 |
Why?
| Blood Platelets | 1 | 2017 | 351 | 0.460 |
Why?
| Endothelial Progenitor Cells | 1 | 2014 | 18 | 0.450 |
Why?
| Adiposity | 3 | 2016 | 457 | 0.440 |
Why?
| Analysis of Variance | 7 | 2016 | 1226 | 0.430 |
Why?
| Infusions, Intra-Arterial | 5 | 2013 | 46 | 0.420 |
Why?
| Anti-HIV Agents | 1 | 2019 | 666 | 0.420 |
Why?
| Colony-Forming Units Assay | 6 | 2014 | 88 | 0.420 |
Why?
| Glucose | 1 | 2017 | 896 | 0.410 |
Why?
| T-Lymphocytes | 2 | 2010 | 1736 | 0.410 |
Why?
| Blood Vessels | 1 | 2014 | 180 | 0.410 |
Why?
| Endothelin A Receptor Antagonists | 4 | 2014 | 24 | 0.400 |
Why?
| Alkalosis, Respiratory | 2 | 2023 | 2 | 0.400 |
Why?
| Coronary Disease | 3 | 2007 | 348 | 0.400 |
Why?
| Young Adult | 11 | 2023 | 10455 | 0.400 |
Why?
| Oxygen Consumption | 11 | 2024 | 588 | 0.400 |
Why?
| Time Factors | 10 | 2021 | 6112 | 0.390 |
Why?
| Risk Factors | 14 | 2018 | 8628 | 0.390 |
Why?
| Glucose Intolerance | 1 | 2013 | 136 | 0.390 |
Why?
| Muscle, Smooth, Vascular | 5 | 2010 | 411 | 0.380 |
Why?
| Fatty Acids | 1 | 2014 | 381 | 0.380 |
Why?
| Abdominal Fat | 1 | 2011 | 39 | 0.370 |
Why?
| Muscle Tonus | 2 | 2010 | 17 | 0.360 |
Why?
| Antigens, CD34 | 1 | 2011 | 89 | 0.360 |
Why?
| Body Composition | 13 | 2009 | 590 | 0.360 |
Why?
| HIV Protease Inhibitors | 1 | 2011 | 64 | 0.360 |
Why?
| HIV-1 | 2 | 2019 | 768 | 0.360 |
Why?
| Dyslipidemias | 1 | 2012 | 154 | 0.350 |
Why?
| Heart Failure | 1 | 2023 | 1945 | 0.350 |
Why?
| Cholesterol, LDL | 1 | 2012 | 307 | 0.350 |
Why?
| Chemotaxis | 1 | 2010 | 130 | 0.340 |
Why?
| Postprandial Period | 3 | 2019 | 87 | 0.340 |
Why?
| Health | 1 | 2010 | 74 | 0.340 |
Why?
| Sleep Wake Disorders | 1 | 2013 | 233 | 0.340 |
Why?
| NF-kappa B | 2 | 2023 | 638 | 0.330 |
Why?
| Feeding Behavior | 1 | 2015 | 574 | 0.330 |
Why?
| Disease | 1 | 2010 | 85 | 0.330 |
Why?
| NG-Nitroarginine Methyl Ester | 2 | 2008 | 38 | 0.330 |
Why?
| Flow Cytometry | 4 | 2019 | 1083 | 0.330 |
Why?
| Vascular Endothelial Growth Factor A | 4 | 2014 | 498 | 0.320 |
Why?
| Inflammation | 4 | 2020 | 2477 | 0.310 |
Why?
| Muscarinic Agonists | 1 | 2008 | 9 | 0.300 |
Why?
| Fasting | 4 | 2019 | 240 | 0.300 |
Why?
| Reactive Oxygen Species | 2 | 2021 | 531 | 0.290 |
Why?
| Reference Values | 7 | 2016 | 742 | 0.290 |
Why?
| omega-N-Methylarginine | 3 | 2015 | 26 | 0.280 |
Why?
| Interleukin-6 | 4 | 2021 | 676 | 0.280 |
Why?
| Endothelin Receptor Antagonists | 4 | 2011 | 58 | 0.280 |
Why?
| Adult Stem Cells | 1 | 2006 | 32 | 0.270 |
Why?
| Epigenesis, Genetic | 1 | 2010 | 520 | 0.260 |
Why?
| Double-Blind Method | 5 | 2021 | 1660 | 0.260 |
Why?
| Dinucleotide Repeats | 1 | 2005 | 4 | 0.260 |
Why?
| Walking | 5 | 2018 | 422 | 0.250 |
Why?
| Hyperthermia, Induced | 2 | 2023 | 65 | 0.250 |
Why?
| Myocardial Ischemia | 1 | 2006 | 235 | 0.240 |
Why?
| Arteries | 6 | 2018 | 247 | 0.240 |
Why?
| Estrogen Receptor alpha | 1 | 2005 | 121 | 0.230 |
Why?
| Age Factors | 8 | 2010 | 2894 | 0.230 |
Why?
| Antihypertensive Agents | 4 | 2013 | 429 | 0.230 |
Why?
| Blood Flow Velocity | 3 | 2012 | 387 | 0.230 |
Why?
| Endothelin B Receptor Antagonists | 2 | 2014 | 11 | 0.230 |
Why?
| Quadriplegia | 1 | 2023 | 12 | 0.220 |
Why?
| Hypertrophy | 2 | 2023 | 109 | 0.220 |
Why?
| von Willebrand Factor | 1 | 2023 | 56 | 0.220 |
Why?
| Actinin | 1 | 2023 | 13 | 0.220 |
Why?
| Thrombophilia | 1 | 2023 | 67 | 0.210 |
Why?
| Troponin T | 1 | 2023 | 49 | 0.210 |
Why?
| Running | 5 | 2000 | 207 | 0.210 |
Why?
| Adipose Tissue | 5 | 2005 | 539 | 0.200 |
Why?
| Vaping | 1 | 2023 | 45 | 0.200 |
Why?
| Receptor, Endothelin B | 2 | 2014 | 51 | 0.200 |
Why?
| Sex Characteristics | 4 | 2017 | 640 | 0.200 |
Why?
| Electronic Nicotine Delivery Systems | 1 | 2023 | 71 | 0.200 |
Why?
| Breathing Exercises | 1 | 2021 | 18 | 0.190 |
Why?
| Inhalation | 1 | 2021 | 26 | 0.190 |
Why?
| Respiratory Muscles | 1 | 2021 | 28 | 0.190 |
Why?
| South America | 1 | 2021 | 51 | 0.190 |
Why?
| Diabetes Mellitus, Type 2 | 3 | 2019 | 2094 | 0.190 |
Why?
| Peru | 1 | 2021 | 54 | 0.190 |
Why?
| Diet, Carbohydrate-Restricted | 2 | 2018 | 28 | 0.180 |
Why?
| Lymphocyte Count | 2 | 2011 | 133 | 0.180 |
Why?
| Fibrosis | 1 | 2023 | 453 | 0.180 |
Why?
| Healthy Lifestyle | 1 | 2021 | 29 | 0.180 |
Why?
| Carotid Arteries | 4 | 2003 | 180 | 0.180 |
Why?
| Transcription Factor RelA | 1 | 2021 | 82 | 0.180 |
Why?
| Endothelins | 1 | 2021 | 61 | 0.180 |
Why?
| Drug Administration Schedule | 2 | 2016 | 718 | 0.180 |
Why?
| Transforming Growth Factor beta | 1 | 2023 | 448 | 0.180 |
Why?
| Tumor Necrosis Factor-alpha | 3 | 2015 | 1139 | 0.180 |
Why?
| Piperidines | 2 | 2013 | 160 | 0.170 |
Why?
| Cytochromes c | 2 | 2010 | 63 | 0.170 |
Why?
| Chemokine CXCL12 | 2 | 2010 | 74 | 0.170 |
Why?
| Interleukin-8 | 1 | 2021 | 237 | 0.170 |
Why?
| Fibrinogen | 2 | 1998 | 154 | 0.170 |
Why?
| Oligopeptides | 2 | 2013 | 236 | 0.170 |
Why?
| Cell Proliferation | 1 | 2006 | 2186 | 0.170 |
Why?
| Colorado | 5 | 2021 | 4099 | 0.170 |
Why?
| Fever | 2 | 2020 | 280 | 0.170 |
Why?
| Physical Exertion | 2 | 1998 | 209 | 0.160 |
Why?
| Insulin Glargine | 1 | 2019 | 73 | 0.160 |
Why?
| Phenotype | 2 | 2021 | 2796 | 0.160 |
Why?
| Risk Reduction Behavior | 1 | 2021 | 201 | 0.160 |
Why?
| Myocytes, Cardiac | 1 | 2023 | 449 | 0.160 |
Why?
| Hemoglobins | 1 | 2021 | 315 | 0.160 |
Why?
| E-Selectin | 1 | 2018 | 53 | 0.160 |
Why?
| HIV Antibodies | 1 | 2019 | 49 | 0.160 |
Why?
| Telomerase | 2 | 2011 | 206 | 0.160 |
Why?
| Infusions, Intravenous | 2 | 2011 | 371 | 0.160 |
Why?
| Follow-Up Studies | 3 | 2017 | 4411 | 0.160 |
Why?
| Heat-Shock Response | 1 | 2018 | 46 | 0.160 |
Why?
| Treatment Outcome | 5 | 2021 | 9084 | 0.160 |
Why?
| Brachial Artery | 3 | 2017 | 176 | 0.160 |
Why?
| Pilot Projects | 1 | 2023 | 1372 | 0.150 |
Why?
| Myocardial Infarction | 1 | 2005 | 927 | 0.150 |
Why?
| Antioxidants | 1 | 2021 | 530 | 0.150 |
Why?
| Exercise Therapy | 3 | 2017 | 350 | 0.150 |
Why?
| Lipids | 3 | 2009 | 580 | 0.150 |
Why?
| Adrenergic beta-1 Receptor Antagonists | 1 | 2017 | 9 | 0.150 |
Why?
| Vascular Cell Adhesion Molecule-1 | 1 | 1997 | 35 | 0.150 |
Why?
| Dietary Carbohydrates | 1 | 2018 | 138 | 0.150 |
Why?
| Heart | 1 | 2021 | 612 | 0.140 |
Why?
| Prognosis | 3 | 2018 | 3328 | 0.140 |
Why?
| Intercellular Adhesion Molecule-1 | 1 | 1997 | 154 | 0.140 |
Why?
| Anthropometry | 2 | 2011 | 182 | 0.130 |
Why?
| Infusions, Intraosseous | 1 | 2016 | 20 | 0.130 |
Why?
| Triglycerides | 3 | 2005 | 467 | 0.130 |
Why?
| Phosphorylation | 1 | 2020 | 1569 | 0.130 |
Why?
| Enzyme Activation | 1 | 2017 | 785 | 0.130 |
Why?
| Hot Temperature | 1 | 2017 | 302 | 0.130 |
Why?
| Substance P | 2 | 2008 | 44 | 0.120 |
Why?
| Isoproterenol | 2 | 2008 | 106 | 0.120 |
Why?
| Down-Regulation | 1 | 2017 | 594 | 0.120 |
Why?
| Blood Circulation | 1 | 2015 | 35 | 0.120 |
Why?
| Cross-Over Studies | 4 | 2017 | 440 | 0.120 |
Why?
| Interleukin-18 | 2 | 2006 | 219 | 0.120 |
Why?
| Peptides | 1 | 2019 | 848 | 0.120 |
Why?
| Signal Transduction | 3 | 2014 | 4509 | 0.120 |
Why?
| Hydrocortisone | 1 | 2015 | 267 | 0.110 |
Why?
| Interleukin-10 | 1 | 2015 | 299 | 0.100 |
Why?
| Regression Analysis | 4 | 2011 | 944 | 0.100 |
Why?
| Hypoglycemic Agents | 1 | 2019 | 1008 | 0.100 |
Why?
| Circadian Rhythm | 1 | 2015 | 354 | 0.100 |
Why?
| Cholinergic Agonists | 1 | 2011 | 7 | 0.100 |
Why?
| Injections, Intravenous | 1 | 2012 | 198 | 0.100 |
Why?
| Blood Volume | 4 | 1999 | 59 | 0.090 |
Why?
| Prevalence | 3 | 2014 | 2249 | 0.090 |
Why?
| Obesity, Abdominal | 1 | 2011 | 37 | 0.090 |
Why?
| Plaque, Atherosclerotic | 1 | 2011 | 44 | 0.090 |
Why?
| Waist Circumference | 1 | 2011 | 122 | 0.090 |
Why?
| Vital Capacity | 2 | 2002 | 255 | 0.090 |
Why?
| Apoptosis Regulatory Proteins | 1 | 2011 | 171 | 0.090 |
Why?
| Femoral Artery | 2 | 2002 | 167 | 0.090 |
Why?
| Cholesterol | 2 | 2005 | 367 | 0.090 |
Why?
| Estrogens | 2 | 2003 | 312 | 0.090 |
Why?
| Plant Lectins | 1 | 2010 | 8 | 0.090 |
Why?
| Staurosporine | 1 | 2010 | 21 | 0.090 |
Why?
| Cerebrovascular Circulation | 2 | 2023 | 221 | 0.090 |
Why?
| Granulocyte Colony-Stimulating Factor | 1 | 2010 | 71 | 0.080 |
Why?
| Bone Diseases, Metabolic | 1 | 2010 | 53 | 0.080 |
Why?
| CD3 Complex | 1 | 2009 | 92 | 0.080 |
Why?
| Immunoenzyme Techniques | 1 | 2009 | 192 | 0.080 |
Why?
| Cell Separation | 1 | 2010 | 291 | 0.080 |
Why?
| Leg | 2 | 2001 | 225 | 0.080 |
Why?
| Phosphatidylinositol 3-Kinases | 1 | 2011 | 329 | 0.080 |
Why?
| Baroreflex | 2 | 2000 | 54 | 0.080 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2011 | 398 | 0.080 |
Why?
| Norepinephrine | 1 | 2009 | 201 | 0.080 |
Why?
| Up-Regulation | 1 | 2012 | 807 | 0.080 |
Why?
| Endothelin-Converting Enzymes | 1 | 2008 | 10 | 0.080 |
Why?
| Aspartic Acid Endopeptidases | 1 | 2008 | 21 | 0.080 |
Why?
| Metalloendopeptidases | 1 | 2008 | 55 | 0.080 |
Why?
| Methacholine Chloride | 1 | 2008 | 47 | 0.080 |
Why?
| Cell Count | 1 | 2008 | 303 | 0.080 |
Why?
| Calcium Channel Blockers | 1 | 2008 | 114 | 0.070 |
Why?
| Life Style | 4 | 2003 | 430 | 0.070 |
Why?
| Hemiplegia | 2 | 1997 | 18 | 0.070 |
Why?
| Risk Assessment | 1 | 2016 | 2967 | 0.070 |
Why?
| Arm | 1 | 2007 | 104 | 0.070 |
Why?
| Coronary Circulation | 1 | 2007 | 133 | 0.070 |
Why?
| Muscle, Skeletal | 3 | 2002 | 1472 | 0.070 |
Why?
| Probability | 1 | 2007 | 289 | 0.070 |
Why?
| Lipoproteins, LDL | 1 | 2006 | 128 | 0.070 |
Why?
| Aged, 80 and over | 5 | 2003 | 6344 | 0.070 |
Why?
| DNA Methylation | 1 | 2010 | 495 | 0.070 |
Why?
| Microscopy, Phase-Contrast | 1 | 2005 | 18 | 0.060 |
Why?
| Thymidine | 1 | 2005 | 58 | 0.060 |
Why?
| Weight Loss | 1 | 2010 | 641 | 0.060 |
Why?
| Bone Marrow Cells | 1 | 2005 | 267 | 0.060 |
Why?
| Thrombosis | 1 | 2007 | 298 | 0.060 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 373 | 0.060 |
Why?
| Anaerobic Threshold | 2 | 2005 | 22 | 0.060 |
Why?
| France | 1 | 2024 | 34 | 0.060 |
Why?
| Hypocapnia | 1 | 2023 | 6 | 0.060 |
Why?
| Hyperventilation | 1 | 2023 | 8 | 0.060 |
Why?
| Adenine | 1 | 2005 | 219 | 0.060 |
Why?
| Oxidation-Reduction | 1 | 2006 | 923 | 0.050 |
Why?
| Body Weight | 2 | 2005 | 868 | 0.050 |
Why?
| Bicycling | 1 | 2024 | 86 | 0.050 |
Why?
| Hypertriglyceridemia | 1 | 2003 | 34 | 0.050 |
Why?
| Fenofibrate | 1 | 2003 | 24 | 0.050 |
Why?
| Muscarinic Antagonists | 1 | 2003 | 25 | 0.050 |
Why?
| Sensitivity and Specificity | 1 | 2007 | 1691 | 0.050 |
Why?
| Physical Education and Training | 1 | 2003 | 62 | 0.050 |
Why?
| Exercise Test | 3 | 2005 | 544 | 0.050 |
Why?
| Polymorphism, Genetic | 1 | 2005 | 610 | 0.050 |
Why?
| Carbon Dioxide | 1 | 2023 | 218 | 0.050 |
Why?
| Carotid Artery Diseases | 1 | 2002 | 57 | 0.050 |
Why?
| Progesterone | 1 | 2003 | 232 | 0.050 |
Why?
| Adrenergic beta-Agonists | 1 | 2002 | 126 | 0.050 |
Why?
| Tunica Intima | 4 | 2002 | 78 | 0.050 |
Why?
| Cardiovascular Physiological Phenomena | 1 | 2000 | 40 | 0.040 |
Why?
| Knee | 1 | 2000 | 51 | 0.040 |
Why?
| Heart Rate | 3 | 1998 | 709 | 0.040 |
Why?
| Predictive Value of Tests | 1 | 2005 | 1796 | 0.040 |
Why?
| Compliance | 3 | 2008 | 46 | 0.040 |
Why?
| Social Class | 1 | 2001 | 204 | 0.040 |
Why?
| Oxygen | 1 | 2024 | 854 | 0.040 |
Why?
| Energy Intake | 2 | 1998 | 427 | 0.040 |
Why?
| Hemorheology | 1 | 2018 | 20 | 0.040 |
Why?
| Drug Combinations | 1 | 2019 | 287 | 0.040 |
Why?
| Body Constitution | 1 | 1998 | 47 | 0.040 |
Why?
| Diet, Fat-Restricted | 1 | 2018 | 73 | 0.040 |
Why?
| Microvessels | 1 | 2018 | 68 | 0.040 |
Why?
| Ultrasonography | 4 | 2002 | 633 | 0.040 |
Why?
| Hemostasis | 1 | 1998 | 67 | 0.040 |
Why?
| United States | 1 | 2014 | 12176 | 0.040 |
Why?
| Premenopause | 4 | 1999 | 106 | 0.040 |
Why?
| Cervical Vertebrae | 1 | 2018 | 100 | 0.040 |
Why?
| Plasminogen Activators | 1 | 1997 | 7 | 0.040 |
Why?
| Gait | 2 | 1997 | 249 | 0.040 |
Why?
| Cohort Studies | 1 | 2007 | 4894 | 0.040 |
Why?
| Vascular Resistance | 1 | 1998 | 337 | 0.040 |
Why?
| Neoplasms | 1 | 2010 | 2097 | 0.030 |
Why?
| Movement Disorders | 1 | 1997 | 48 | 0.030 |
Why?
| Cerebrovascular Disorders | 1 | 1997 | 82 | 0.030 |
Why?
| Chromium | 1 | 1996 | 12 | 0.030 |
Why?
| Leukocytes, Mononuclear | 1 | 2018 | 493 | 0.030 |
Why?
| Weight Lifting | 1 | 1996 | 29 | 0.030 |
Why?
| Insulin | 1 | 2005 | 2076 | 0.030 |
Why?
| Hypoxia | 1 | 2021 | 957 | 0.030 |
Why?
| Combined Modality Therapy | 1 | 2017 | 1121 | 0.030 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2019 | 1214 | 0.030 |
Why?
| Antigens | 1 | 1996 | 318 | 0.030 |
Why?
| Melatonin | 1 | 2015 | 105 | 0.030 |
Why?
| Swimming | 3 | 1999 | 44 | 0.030 |
Why?
| Menopause | 1 | 1997 | 271 | 0.030 |
Why?
| Defibrillators, Implantable | 1 | 1997 | 286 | 0.030 |
Why?
| Brain Ischemia | 1 | 1997 | 299 | 0.030 |
Why?
| Tunica Media | 2 | 2001 | 35 | 0.020 |
Why?
| Sex Factors | 1 | 1996 | 1715 | 0.020 |
Why?
| Brain | 1 | 2020 | 2371 | 0.020 |
Why?
| Cardiac Output | 2 | 1998 | 143 | 0.020 |
Why?
| Prospective Studies | 4 | 2001 | 6217 | 0.020 |
Why?
| Bone Density | 1 | 2010 | 432 | 0.020 |
Why?
| Stroke Volume | 2 | 1998 | 504 | 0.020 |
Why?
| Adolescent | 5 | 2002 | 17831 | 0.020 |
Why?
| Hemostatics | 1 | 2005 | 47 | 0.010 |
Why?
| Hypolipidemic Agents | 1 | 2003 | 86 | 0.010 |
Why?
| Fatty Acids, Nonesterified | 1 | 2003 | 151 | 0.010 |
Why?
| Lipoproteins | 1 | 2003 | 159 | 0.010 |
Why?
| Absorptiometry, Photon | 1 | 2002 | 224 | 0.010 |
Why?
| Blood Viscosity | 1 | 2001 | 16 | 0.010 |
Why?
| Habits | 1 | 2001 | 36 | 0.010 |
Why?
| Thoracic Arteries | 1 | 2000 | 4 | 0.010 |
Why?
| Thigh | 1 | 2000 | 53 | 0.010 |
Why?
| Mexico | 1 | 2001 | 162 | 0.010 |
Why?
| Thinness | 1 | 2000 | 87 | 0.010 |
Why?
| Elasticity | 1 | 2000 | 189 | 0.010 |
Why?
| Erythrocyte Volume | 1 | 1999 | 4 | 0.010 |
Why?
| Femur | 1 | 2001 | 191 | 0.010 |
Why?
| Plasma Volume | 1 | 1999 | 13 | 0.010 |
Why?
| Stress, Mechanical | 1 | 2001 | 445 | 0.010 |
Why?
| Supine Position | 1 | 1998 | 32 | 0.010 |
Why?
| Posture | 1 | 1999 | 152 | 0.010 |
Why?
| Signal Processing, Computer-Assisted | 1 | 1998 | 133 | 0.010 |
Why?
| Hematocrit | 1 | 1997 | 87 | 0.010 |
Why?
| Rest | 1 | 1997 | 103 | 0.010 |
Why?
| Electric Conductivity | 1 | 1997 | 88 | 0.010 |
Why?
| Ventricular Fibrillation | 1 | 1997 | 51 | 0.010 |
Why?
| Electrodes, Implanted | 1 | 1997 | 91 | 0.010 |
Why?
| Hyperlipidemias | 1 | 1997 | 121 | 0.010 |
Why?
| Electrocardiography | 1 | 1998 | 560 | 0.010 |
Why?
| Diabetes Complications | 1 | 1997 | 211 | 0.010 |
Why?
| Tachycardia, Ventricular | 1 | 1997 | 152 | 0.010 |
Why?
| Equipment Design | 1 | 1997 | 508 | 0.010 |
Why?
| Insulin Resistance | 1 | 2003 | 1072 | 0.010 |
Why?
| Multivariate Analysis | 1 | 1998 | 1430 | 0.010 |
Why?
| Animals | 2 | 2008 | 31694 | 0.010 |
Why?
| Kinetics | 1 | 1997 | 1551 | 0.010 |
Why?
| Stroke | 1 | 2002 | 1021 | 0.010 |
Why?
| Heart Arrest | 1 | 1997 | 292 | 0.010 |
Why?
| Survival Rate | 1 | 1997 | 1644 | 0.010 |
Why?
| Length of Stay | 1 | 1997 | 962 | 0.010 |
Why?
| Energy Metabolism | 1 | 1997 | 731 | 0.010 |
Why?
| Smoking | 1 | 1997 | 1380 | 0.010 |
Why?
| Retrospective Studies | 1 | 2003 | 12542 | 0.000 |
Why?
|
|
DeSouza's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|